bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S5 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary Figure 5: ISTH1047 or ISTH0047 reduce glioma cell migration.
Supplementary materials from Novel Targeting of Transcription and Metabolism in Glioblastoma
Authors: Su Yu-Ting , Chen Robert , Wang Herui , Song Hua , Zhang Qi , Chen Li-Yuan , Lappin Hallie , Vasconcelos Gabriel , Lita Adrian , Maric Dragan , Li Aiguo , Celiku Orieta , Zhang Wei , Meetze Kristan , Estok Thomas , Larion Mioara , Abu-Asab Mones , Zhuang Zhengping , Yang Chunzhang , Gilbert Mark R. , Wu Jing
Published: April 2023

Figure S1. The effects of TG02 in U251 cells Figure S2. Protein expressions of p53 and Stat3 in GSC923 and U251-treated cells. Figure S3. TG02 induces cell apoptosis and synergizes with TMZ in GBM Figure S4. The effects of TG02, TMZ, and TG02/TMZ in GSC923, GSC827 and U251 cells
Supplemental Table 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Authors: Horn Leora , Infante Jeffrey R. , Reckamp Karen L. , Blumenschein George R. , Leal Ticiana A. , Waqar Saiama N. , Gitlitz Barbara J. , Sanborn Rachel E. , Whisenant Jennifer G. , Du Liping , Neal Joel W. , Gockerman Jon P. , Dukart Gary , Harrow Kimberly , Liang Chris , Gibbons James J. , Holzhausen Allison , Lovly Christine M. , Wakelee Heather A.
Published: April 2023

The key pharmacokinetic (PK) parameters (Supplemental Table 3) at the recommended phase 2 dose of 225 mg show that food has minimal impact on absorption of ensartinib.
Supplemental Table 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Authors: Horn Leora , Infante Jeffrey R. , Reckamp Karen L. , Blumenschein George R. , Leal Ticiana A. , Waqar Saiama N. , Gitlitz Barbara J. , Sanborn Rachel E. , Whisenant Jennifer G. , Du Liping , Neal Joel W. , Gockerman Jon P. , Dukart Gary , Harrow Kimberly , Liang Chris , Gibbons James J. , Holzhausen Allison , Lovly Christine M. , Wakelee Heather A.
Published: April 2023

The mean concentration of ensartinib in plasma and skin at multiple time points after a single dose of 50 mg/kg is listed in Supplemental Table 2. At 12 hours post-dose, the concentration of ensartinib was 9.0 higher in the skin than in the plasma.
Supplemental Table 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Authors: Horn Leora , Infante Jeffrey R. , Reckamp Karen L. , Blumenschein George R. , Leal Ticiana A. , Waqar Saiama N. , Gitlitz Barbara J. , Sanborn Rachel E. , Whisenant Jennifer G. , Du Liping , Neal Joel W. , Gockerman Jon P. , Dukart Gary , Harrow Kimberly , Liang Chris , Gibbons James J. , Holzhausen Allison , Lovly Christine M. , Wakelee Heather A.
Published: April 2023

Ensartinib was tested against wild-type ALK and 17 ALK variants in the Reaction Biology panel. Ensartinib potently inhibited all evaluated ALK variants, with in vitro IC50s <4 nM.
Supplemental Figure 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Authors: Horn Leora , Infante Jeffrey R. , Reckamp Karen L. , Blumenschein George R. , Leal Ticiana A. , Waqar Saiama N. , Gitlitz Barbara J. , Sanborn Rachel E. , Whisenant Jennifer G. , Du Liping , Neal Joel W. , Gockerman Jon P. , Dukart Gary , Harrow Kimberly , Liang Chris , Gibbons James J. , Holzhausen Allison , Lovly Christine M. , Wakelee Heather A.
Published: April 2023

Supplemental Figure 1. Representative example from one patient showing the rash that was most frequently observed with ensartinib. The white arrow in the top figure points to the rash that is circled in the bottom figure.
Supplemental Figure S6A from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

Gating strategy used to determine PR1-CTL frequency in peripheral blood of multiple myeloma patients following allogenic stem cell transplantation
Supplemental Figure S3 from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

Absence of PR1 cross-presentation in HLA-A2 negative cell lines
Table S1 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Authors: Zhang Wei , Liu Bo , Wu Wenhui , Li Likun , Broom Bradley M. , Basourakos Spyridon P. , Korentzelos Dimitrios , Luan Yang , Wang Jianxiang , Yang Guang , Park Sanghee , Azad Abul Kalam , Cao Xuhong , Kim Jeri , Corn Paul G. , Logothetis Christopher J. , Aparicio Ana M. , Chinnaiyan Arul M. , Navone Nora , Troncoso Patricia , Thompson Timothy C.
Published: April 2023

DNA damage response and mitotic cell cycle (DDR-M) genes and pathways
Online-Only Tables: 1 and Online-Only Figures: 2 from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Authors: Loibl Sibylle , Weber Karsten , Huober Jens , Krappmann Kristin , Marmé Frederik , Schem Christian , Engels Knut , Pfitzner Berit Maria , Kümmel Sherko , Furlanetto Jenny , Hartmann Arndt , Darb-Esfahani Silvia , Müller Volkmar , Staebler Annette , von Minckwitz Gunter , Kronenwett Ralf , Denkert Carsten
Published: April 2023

Supplementary Table 1: Multivariate analysis of the continuous mEPclin and CPS-EG scores including Ki67 status according to DFS Supplementary Figures
Table S5 from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Authors: Aisner Dara L. , Sholl Lynette M. , Berry Lynne D. , Rossi Michael R. , Chen Heidi , Fujimoto Junya , Moreira Andre L. , Ramalingam Suresh S. , Villaruz Liza C. , Otterson Gregory A. , Haura Eric , Politi Katerina , Glisson Bonnie , Cetnar Jeremy , Garon Edward B. , Schiller Joan , Waqar Saiama N. , Sequist Lecia V. , Brahmer Julie , Shyr Yu , Kugler Kelly , Wistuba Ignacio I. , Johnson Bruce E. , Minna John D. , Kris Mark G. , Bunn Paul A. , Kwiatkowski David J.
Published: April 2023

Supplemental Table 5. All subjects with all molecular results in LCMC2.
Supplemental Figures from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Authors: Aisner Dara L. , Sholl Lynette M. , Berry Lynne D. , Rossi Michael R. , Chen Heidi , Fujimoto Junya , Moreira Andre L. , Ramalingam Suresh S. , Villaruz Liza C. , Otterson Gregory A. , Haura Eric , Politi Katerina , Glisson Bonnie , Cetnar Jeremy , Garon Edward B. , Schiller Joan , Waqar Saiama N. , Sequist Lecia V. , Brahmer Julie , Shyr Yu , Kugler Kelly , Wistuba Ignacio I. , Johnson Bruce E. , Minna John D. , Kris Mark G. , Bunn Paul A. , Kwiatkowski David J.
Published: April 2023

Supplementary Figure 1 Sample Analysis Flowchart Supplementary Figure 2 LOMC2 Gene List Supplementary Figure 3 PTEN Immunohistochemistry analysis of LCMC II samples. Supplementary Figure 4 Mutation Frequency by Mutation and Smoking Status
Figure S4 from BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Authors: Sanlorenzo Martina , Vujic Igor , Floris Arianna , Novelli Mauro , Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Rotolo Ramona , Donini Chiara , Basiricò Marco , Quaglino Pietro , Fierro Maria Teresa , Giordano Silvia , Sibilia Maria , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Fig. S4. PD1+ melanoma cells proliferate less than their PD1- counterpart. A representative proliferation assay is shown. The proliferation of PD1+ and PD1- mMel2 patient-derived melanoma cells was evaluated by the vital dye CFSE staining and fluorescence intensity decrement over time.
Figure S1 from BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Authors: Sanlorenzo Martina , Vujic Igor , Floris Arianna , Novelli Mauro , Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Rotolo Ramona , Donini Chiara , Basiricò Marco , Quaglino Pietro , Fierro Maria Teresa , Giordano Silvia , Sibilia Maria , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Fig. S1. PD1 expression on melanoma correlates with PDL1 and PDL2. Scatter plots depicturing the correlation between (A) PD1 and PDL1, (B) PD1 and PDL2, (C) PDL1 and PDL2 in the 214 melanoma samples analyzed from the TCGA.
FIgure S2 from BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Authors: Sanlorenzo Martina , Vujic Igor , Floris Arianna , Novelli Mauro , Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Rotolo Ramona , Donini Chiara , Basiricò Marco , Quaglino Pietro , Fierro Maria Teresa , Giordano Silvia , Sibilia Maria , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Fig. S2. BRAF/MEKi increase rates of PD1+ and PDL2+ melanoma cells. Rates of (A) PD1, (B) PDL1, (C) PDL2 positive melanoma cells after treatment with BRAF/MEKi [dabrafenib+trametinib [1 mcM+5nM] in BRAFV600 mutant cell lines and trametinib [5nM] in the NRASQ61 mutant cell line for 96 hours]. *p<0.05, **p<0,001, n.s = not significant.
Supplementary Figures from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Authors: Magrangeas Florence , Kuiper Rowan , Avet-Loiseau Hervé , Gouraud Wilfried , Guérin-Charbonnel Catherine , Ferrer Ludovic , Aussem Alexandre , Elghazel Haytham , Suhard Jérôme , Der Sakissian Henri , Attal Michel , Munshi Nikhil C. , Sonneveld Pieter , Dumontet Charles , Moreau Philippe , van Duin Mark , Campion Loïc , Minvielle Stéphane
Published: April 2023

Supplementary Figure 1. Subjects and single SNP exclusion schema for the GWAS Supplementary Figure 2. Principal component plot for the genotyped IFM cohort and 3 HapMap phase III reference populations. The first two components are plotted, each sample is represented by a colored circle. Magenta: IFM samples; Red : IFM outliers; Pink: Utah residents with Northern and Western European ancestry from the CEPH collection (CEU); Green: Han Chinese in Beijing, China (CHB); Blue: Yoruba in Ibadan, Nigeria (YRI). Supplementary Figure 3. OR for 6 SNPs associated with BiPN discovery study ; for each allele, OR and CI is drawn (left: 0 risk-allele, middle :1 risk-allele, right: 2 risk-allele). Supplementary Figure 4. Manhattan plots for association analyses. Genome-wide association test results are shown as -Log10 transformed P-values . Chromosomal location of SNPs is indicated on the x-axis. The five candidate gene SNPs are indicated.
Tale S3 from LncRNA–FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling
Authors: Bian Zehua , Zhang Jiwei , Li Min , Feng Yuyang , Wang Xue , Zhang Jia , Yao Surui , Jin Guoying , Du Jun , Han Weifeng , Yin Yuan , Huang Shenglin , Fei Bojian , Zou Jian , Huang Zhaohui
Published: April 2023

Tale S3
Supplementary Figure 1 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Authors: Mercogliano María F. , De Martino Mara , Venturutti Leandro , Rivas Martín A. , Proietti Cecilia J. , Inurrigarro Gloria , Frahm Isabel , Allemand Daniel H. , Deza Ernesto Gil , Ares Sandra , Gercovich Felipe G. , Guzmán Pablo , Roa Juan C. , Elizalde Patricia V. , Schillaci Roxana
Published: April 2023

Supplementary Figure S1. Aggressive features of tumors overexpressing TNFα. A-C, H&E staining of BT-474 T2 tumors showing A, muscle and B, dermis infiltration (depicted by arrows). C, peritumor leukocyte infiltration (arrow). D, histopathological analysis of BT-474 T1 tumors. BT-474 T1 tumors were established and treated as described in Figure 2. First and second lines are H&E stainings and third line depicts HER2 staining by IHC. Arrows point out mitotic figures.
Supplementary Table 10 from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Table 10
Supplemental legend from Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Authors: Segal Neil H. , He Aiwu R. , Doi Toshihiko , Levy Ronald , Bhatia Shailender , Pishvaian Michael J. , Cesari Rossano , Chen Ying , Davis Craig B. , Huang Bo , Thall Aron D. , Gopal Ajay K.
Published: April 2023

Supplemental legend
Supplementary figure, tables and information from BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer
Authors: Liu Xiyou , Kumar Manish , Yang Liangpeng , Molkentine David P. , Valdecanas David , Yu Shiying , Meyn Raymond E. , Heymach John V. , Skinner Heath D.
Published: April 2023

Supplementary Figure 1 HN31 cells with BAP1 vector control, knockdown, and wild-type variants were immunoblotted for the expression of various proteins associated with the DNA damage response (both homologous recombination [BAP1] and non-homologous end-rejoining [CHK1, CHK2, p53]) after a 4Gy dose of radiation. BAP1 knockdown did not affect levels of NHEJ proteins. Supplementary Table 1: Antibody information Supplementary Table 2: Cell line information
Supplementary Figure 3 from Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring
Authors: Guffroy Magali , Falahatpisheh Hadi , Biddle Kathleen , Kreeger John , Obert Leslie , Walters Karen , Goldstein Richard , Boucher Germaine , Coskran Timothy , Reagan William , Sullivan Danielle , Huang Chunli , Sokolowski Sharon , Giovanelli Richard , Gerber Hans-Peter , Finkelstein Martin , Khan Nasir
Published: April 2023

There were no significant PF-0259-related changes in IL-6 throughout the study. Data are represented as mean ratios to baseline {plus minus} 1 standard deviation (SD).
Supplementary Figure 2 from Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring
Authors: Guffroy Magali , Falahatpisheh Hadi , Biddle Kathleen , Kreeger John , Obert Leslie , Walters Karen , Goldstein Richard , Boucher Germaine , Coskran Timothy , Reagan William , Sullivan Danielle , Huang Chunli , Sokolowski Sharon , Giovanelli Richard , Gerber Hans-Peter , Finkelstein Martin , Khan Nasir
Published: April 2023

PF-0259 did not induce platelet sequestration in spleen. Monkeys were dosed intravenously with vehicle or PF-0259 at 6 mg/m2/dose once every 3 weeks and were necropsied on Day 3 (at the time of platelet nadirs) or on Day 63 (at the end of the 3rd cycle). CD41 IHC for platelets was performed on spleen samples from vehicle control (A, C) and PF-0259-dosed (B, D) monkeys on Day 3 and Day 63. There was no evidence of increased CD41 immunostaining in PF-0259-dosed monkeys on Day 3 (B) or Day 63 (D) as compared with vehicle control monkeys (A and C, respectively), indicating lack of splenic sequestration of platelets at both time points. Noteworthy was a reduced CD41 immunostaining in PF-0259-dosed monkeys as compared with the control monkey on Day 3, indicating release of platelets from the spleen storage pool secondary to PF-0259-related acute thrombocytopenia. Scale bar = 60 Âµm.
Suppl. Figure 5 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

Representative images of immunohistochemical stainings of the isotype controls IgG and IgG1 in normal brain (NB) tissues, astrocytomas (WHO{degree sign}II: n = 10; WHO{degree sign}III: n = 10), and oligodendrogliomas (WHO{degree sign}II: n = 10; WHO{degree sign}III: n = 10). Scale bar: 50 Âµm.
Table S1 from Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Authors: Norquist Barbara M. , Brady Mark F. , Harrell Maria I. , Walsh Tom , Lee Ming K. , Gulsuner Suleyman , Bernards Sarah S. , Casadei Silvia , Burger Robert A. , Tewari Krishnansu S. , Backes Floor , Mannel Robert S. , Glaser Gretchen , Bailey Cheryl , Rubin Stephen , Soper John , Lankes Heather A. , Ramirez Nilsa C. , King Mary Claire , Birrer Michael J. , Swisher Elizabeth M.
Published: April 2023

Table of non-BRCA mutations with clinical characteristics
Suppl. Figure 2 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

IFN-ð�›¾ ELISpot raw data to validate antigen immunogenicity in patients of origin. Antigens with a significant increased immunogenicity (grey bars and asterisks) or 1.3-fold increased levels of immune responses (grey bars) were further validated in a bigger study sample of healthy individuals and lower-grade glioma patients. Solid line represents mean background of negative control (IgG1). (*, p < 0.05; **, p < 0.01; ***, p < 0.001)
Supplementary Figure S1-S3 from Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models
Authors: Kogiso Mari , Qi Lin , Braun Frank K. , Injac Sarah G. , Zhang Linna , Du Yuchen , Zhang Huiyuan , Lin Frank Y. , Zhao Sibo , Lindsay Holly , Su Jack M. , Baxter Patricia A. , Adesina Adekunle M. , Liao Debra , Qian Mark G. , Berg Stacey , Muscal Jodi A. , Li Xiao-Nan
Published: April 2023

Supplementary Figure S1-S3 Figure S1. Anti-proliferative effects of MLN8237 on pGBM cell lines. Paired monolayer (Mono) and neurosphere (NS) of IC-4687GBM, IC-3752GBM and ICR0315GBM were seeded at 2,000 cells/well and exposed to MLN8237 (1 - 4,000 nM) and anti-proliferative effect was assessed by staining with 250 Âµg/mL of MTT for 4 hrs at day 11. Viable cells were stained with dark colored intracellular crystal. (Bar=100 Âµm) Figure S2. FCM analysis of cell cycle distribution in vitro and in vivo. A. In vitro analysis was performed in paired monolayer (Mono) and neurosphere (NS) cells of IC-4687GBM, IC-3752GBM and IC-R0315GBM. Both dose-responses (on day 7) (left panel) and time-course change (at 62.5 nM) (right panel) were examined and presented as percentages of G0 /G1 , S and G2 /M phase in alive cells. Â€ P<0.05, *P<0.01 compared to the untreated (0 nM) cells. B. In vivo changes of cell cycle distribution were analyzed in IC-4687GBM cells treated by MLN8237 (30 mg/kg/day for 12 days by gavage). In addition to the recurrent tumors (Recurrent) harvested when the mice became moribund in the survival group, a separate group of tumors harvested 1 hr post the last treatment of MLN8237 (30 mg/kg/day for 12 days by gavage) (End of Treatment samples) were also included. DNA/RNA were stained with Hoechst 33342/Pyronin Y followed by mouse antibody cocktail staining (to gate out mouse cells) and analyzed by FCM. Representative DNA/RNA profiles (upper panel) and percentage of G0 , G1 , S and G2 /M phase in cell cycle (lower panel) were presented. Figure S3. Representative images of IHC of ARUKA. A. Representative images of AURKA in IC-4687GBM xenograft showing the cells with different staining intensity (arrow) (Magnification: x40). B. AURKA protein expression in IC-R0315GBM in the vehicle treated control and in the recurrent tumor (magnification: x40).
Table S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Table S1
Figure S3 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Supplemental Figure S3: Istiratumab induces ubiquitination of IGF-1R and ErbB3
Table S2 from Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival
Authors: Vandeven Natalie , Lewis Christopher W. , Makarov Vladimir , Riaz Nadeem , Paulson Kelly G. , Hippe Daniel , Bestick Amy , Doumani Ryan , Marx Tessa , Takagishi Seesha , Chan Timothy A. , Choi Jaehyuk , Nghiem Paul
Published: April 2023

Summary of patients receiving immunotherapies
Table S1 from Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival
Authors: Vandeven Natalie , Lewis Christopher W. , Makarov Vladimir , Riaz Nadeem , Paulson Kelly G. , Hippe Daniel , Bestick Amy , Doumani Ryan , Marx Tessa , Takagishi Seesha , Chan Timothy A. , Choi Jaehyuk , Nghiem Paul
Published: April 2023

Patients with unknown primary lesions and without immunosuppression have improved survival among patients with stage IIIB and stage IV MCC
Figure S1 from Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival
Authors: Vandeven Natalie , Lewis Christopher W. , Makarov Vladimir , Riaz Nadeem , Paulson Kelly G. , Hippe Daniel , Bestick Amy , Doumani Ryan , Marx Tessa , Takagishi Seesha , Chan Timothy A. , Choi Jaehyuk , Nghiem Paul
Published: April 2023

Supplementary Figure 1. MCC-UP status predicts better overall but not recurrence-free survival among patients with stage IV disease. Panel A depicts overall survival and panel B depicts recurrence-free survival among 20 stage IV MCC patients. Overall and recurrence-free survival were performed using a Cox-proportional hazards model.
Supplementary Appendix 1 from High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer
Authors: Diets Illja J. , Waanders Esmé , Ligtenberg Marjolijn J. , van Bladel Diede A.G. , Kamping Eveline J. , Hoogerbrugge Peter M. , Hopman Saskia , Olderode-Berends Maran J. , Gerkes Erica H. , Koolen David A. , Marcelis Carlo , Santen Gijs W. , van Belzen Martine J. , Mordaunt Dylan , McGregor Lesley , Thompson Elizabeth , Kattamis Antonis , Pastorczak Agata , Mlynarski Wojciech , Ilencikova Denisa , van Silfhout Anneke Vulto- , Gardeitchik Thatjana , de Bont Eveline S. , Loeffen Jan , Wagner Anja , Mensenkamp Arjen R. , Kuiper Roland P. , Hoogerbrugge Nicoline , Jongmans Marjolijn C.
Published: April 2023

Supplementary Table S1 - Cancer gene panel Supplementary Table S2 - Patients with multiple malignancies Supplementary Table S3 - Tumor types of index patients Supplementary Table S4 - Candidate genes Supplementary Table S5 - Overview of clinical features and mutations found in category 1 (ID and/or congenital anomalies) Supplementary Table S6 - Overview of clinical features and mutations found in category 2 (cancer twice) Supplementary Table S7 - Overview of clinical features and mutations found in category 3 (family history) Supplementary Table S8 - Overview of clinical features and mutations found in category 4 (adult type of cancer) Supplementary Table S9 - Overview of clinical features and mutations found in category 5 (multiple reasons for inclusion) Supplementary Figure S1 - Detection of mosaic mutation in ARID1A Supplementary Figure S2 - Family tree of case #04 Supplementary Figure S3 - Family tree of case #05 Supplementary Figure S4 - Family tree of case #07 Supplementary Figure S5 - Family tree of case #10 Supplementary Figure S6 - Family tree of case #12 Supplementary Figure S7 - Family tree of case #17 Supplementary Figure S8 - Family tree of case #21 Supplementary Figure S9 - Family tree of case #22 Supplementary Figure S10 - Family tree of case #24 Supplementary Figure S11 - Family tree of case #27 Supplementary Figure S12 - Family tree of case #28 Supplementary Figure S13 - Family tree of case #29 Supplementary Figure S14 - Family tree of case #34 Supplementary Figure S15 - Family tree of case #36 Supplementary Figure S16 - Family tree of case #39
Table S2 from 5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial
Authors: Maytin Edward V. , Anand Sanjay , Riha Margo , Lohser Sara , Tellez Alejandra , Ishak Rim , Karpinski Lauren , Sot Janine , Hu Bo , Denisyuk Anton , Davis Scott C. , Kyei Angela , Vidimos Allison
Published: April 2023

PpIX accumulation in AK lesions measured by two different techniques
Figure S3 from 5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial
Authors: Maytin Edward V. , Anand Sanjay , Riha Margo , Lohser Sara , Tellez Alejandra , Ishak Rim , Karpinski Lauren , Sot Janine , Hu Bo , Denisyuk Anton , Davis Scott C. , Kyei Angela , Vidimos Allison
Published: April 2023

Absolute and relative lesion counts for AK at all body site of all study patients
Table S1 from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Authors: Greif Philipp A. , Hartmann Luise , Vosberg Sebastian , Stief Sophie M. , Mattes Raphael , Hellmann Ines , Metzeler Klaus H. , Herold Tobias , Bamopoulos Stefanos A. , Kerbs Paul , Jurinovic Vindi , Schumacher Daniela , Pastore Friederike , Bräundl Kathrin , Zellmeier Evelyn , Ksienzyk Bianka , Konstandin Nikola P. , Schneider Stephanie , Graf Alexander , Krebs Stefan , Blum Helmut , Neumann Martin , Baldus Claudia D. , Bohlander Stefan K. , Wolf Stephan , Görlich Dennis , Berdel Wolfgang E. , Wörmann Bernhard J. , Hiddemann Wolfgang , Spiekermann Karsten
Published: April 2023

Summary patient characteristics
Supplementary Figures from Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Authors: Gupta Santosh , Li Jing , Kemeny Gabor , Bitting Rhonda L. , Beaver Joshua , Somarelli Jason A. , Ware Kathryn E. , Gregory Simon , Armstrong Andrew J.
Published: April 2023

Figure S1: Reference genomic data in cell lines aCGH. A) Male vs. female. B) Leucocyte vs. T47D cells spiked in blood. C) Male vs. LNCaP. D) ERBB1 and SIX1 amplification in T47D cells spiked into the blood. E) PTEN loss in LNCaP; Figure S2: Data reliability and reproducibility of aCGH experiments. A) a; Sample P36.1 and its replicate, b; Overlap in P36.1 and the P36.1-replicate and c; AR amplification in both independent experiments. B) a; P37.3 and its dye swap, b; Genes comparison in P37.3 vs. P37.3 replicate; Figure S3: CGH array gene view images from selected mCRPC clinical CTCs samples depicting gain in selected regions. A) AR, B) FOXA1, C) CDK12, D) BRD4, E) PXN, F) ABL1 and G) NCOA2; Figure S4: Chromosomal aberration of PI3K family members in patient P32.1 and P32.2 CTCs. A) Copy gains (red) and losses (blue), or copy neutral (white) regions in mCRPC CTCs. B) BTK gain was observed in P32.1 and loss in P32.2 CTCs aCGH analysis.
Supplementary Figures S1 and S2 and Supplementary Tables S1 and S2 from Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
Authors: Lipton Allan , Smith Matthew R. , Fizazi Karim , Stopeck Alison T. , Henry David , Brown Janet E. , Shore Neal D. , Saad Fred , Spencer Andrew , Zhu Li , Warner Douglas J.
Published: April 2023

Supplementary Figure S1: Combined patient population and treatments in the three phase III studies included in the analysis. Supplementary Figure S2: OS (A), DP (B), and DPB (C) stratified by category ({greater than or equal to} or < median) of month 3 sBSAP percent change from baseline. Supplementary Table S1: BTM levels at baseline and at month 3 after bone antiresorptive treatment. Supplementary Table S2: Covariate analysis of OS, DP, and DPB at month 3 adjusted for baseline visceral metastases, bone metastases, or ECOG category.
Supplemental Table 2 from Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
Authors: Yang Qingshan , Chen Lisa S. , Ha Min Jin , Do Kim-Anh , Neelapu Sattva S. , Gandhi Varsha
Published: April 2023

Supplemental Table 2. Patient diagnosis, leukocyte types and cytogenetics information
Table S1 from A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer
Authors: Gaponova Anna V. , Nikonova Anna S. , Deneka Alexander Y. , Kopp Meghan C. , Kudinov Alexander E. , Skobeleva Natalia , Khazak Vladimir , Ogawa Luisa S. , Cai Kathy Q. , Duncan Kelly E. , Duncan James S. , Egleston Brian L. , Proia David A. , Boumber Yanis , Golemis Erica A.
Published: April 2023

Supplemental Table 1
Supplemental Figures 1 - 4 from Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
Authors: Yang Qingshan , Chen Lisa S. , Ha Min Jin , Do Kim-Anh , Neelapu Sattva S. , Gandhi Varsha
Published: April 2023

Supplemental Figure 1. Effect of idelalisib on the cell cycle in MCL cell lines and primary cells. Supplemental Figure 2. Effect of idelalisib treatment on the AKT/mTOR-mediated translation regulation pathway in MCL cell lines. Supplemental Figure 3. Relationship of protein synthesis inhibition with growth inhibition and decrease of protein phosphorylation targets by idelalisib treatment in MCL lines and primary cells. Supplemental Figure 4. Composite immunoblot panels for MCL cell lines and primary cells to explain use of loading control in different figures.
Supplemental Methods from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy
Authors: Monk Bradley J. , Facciabene Andrea , Brady William E. , Aghajanian Carol A. , Fracasso Paula M. , Walker Joan L. , Lankes Heather A. , Manjarrez Kristi L. , Danet-Desnoyers Gwenn-äel H. , Bell-McGuinn Katherine M. , McCourt Carolyn K. , Malykhin Alexander , Hershberg Robert M. , Coukos George
Published: April 2023

Supplemental Methods
Supplemental Figures from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy
Authors: Monk Bradley J. , Facciabene Andrea , Brady William E. , Aghajanian Carol A. , Fracasso Paula M. , Walker Joan L. , Lankes Heather A. , Manjarrez Kristi L. , Danet-Desnoyers Gwenn-äel H. , Bell-McGuinn Katherine M. , McCourt Carolyn K. , Malykhin Alexander , Hershberg Robert M. , Coukos George
Published: April 2023

Supplemental Figure 1 Species-specific activation of TLR8 by motolimod. Supplemental Figure 2 Full human immune cell reconstitution in NSG-HIS mice. Supplemental Figure 3 Response to PLD + motolimod is not schedule-sensitive in the NSG-HIS mouse. Supplemental Figure 4 Assessment of macrophage-induced apoptosis using motolimod in combination with PLD. Supplemental Figure 5 Isolation of tumor-infiltrating T cells with specific tumor recognition and lysis ex vivo. Supplemental Figure 6 Pharmacokinetic (PK) evaluations. Supplemental Figure 7 Biological efficacy of motolimod in combination with paclitaxel.
Supplementary figure S3 from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Authors: Jdey Wael , Thierry Sylvain , Russo Christophe , Devun Flavien , Al Abo Muthana , Noguiez-Hellin Patricia , Sun Jian-Sheng , Barillot Emmanuel , Zinovyev Andrei , Kuperstein Inna , Pommier Yves , Dutreix Marie
Published: April 2023

Supplementary figure S3. Estimation and functions of genes uniquely correlated with sensitivity to AsiDNA or olaparib. (A) Number of non-overlapping genes correlated with survival to AsiDNA and Ola. Relationship between the number of non-overlapping genes and the p-value from LOO Spearman correlation analysis of expression data from BC cell lines. (B) Atlas of Cancer Signaling Network (ACSN) global map. (C, D) Coverage of ACSN map with unique genes correlated with survival to AsiDNA or Ola in BC cell lines. Distribution of non-overlapping genes robustly correlated with survival to AsiDNA (C) or Ola (D). Red - Positive correlation with survival to treatment; Green - Negative correlation with survival to treatment. Functional modules as WNT-canonical, Cell-matrix adhesion, Cell polarity, MOMP are implicated in survival to both treatments, but regulated in an opposite manner.
Supplementary materials and methods from Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms
Authors: Lee JongBok , Minden Mark D. , Chen Weihsu C. , Streck Elena , Chen Branson , Kang Hyeonjeong , Arruda Andrea , Ly Dalam , Der Sandy D. , Kang Sohyeong , Achita Paulina , D'Souza Cheryl , Li Yueyang , Childs Richard W. , Dick John E. , Zhang Li
Published: April 2023

Additional information on materials and methods used in this study
Supplementary Tables S2A and S2B from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

Single-nucleotide polymorphisms identified by direct sequencing of the CDA gene in breast cell lines (S2A) and NCI60 cell lines (S2B).
Supplementary Figure S2 from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

Experiments related to studies on the silencing of CDA gene expression.
Table S3 from Expression and Therapeutic Potential of SOX9 in Chordoma
Authors: Chen Hua , Garbutt Cassandra C. , Spentzos Dimitrios , Choy Edwin , Hornicek Francis J. , Duan Zhenfeng
Published: April 2023

. List of primary antibodies used in this study.
Table S1 from Expression and Therapeutic Potential of SOX9 in Chordoma
Authors: Chen Hua , Garbutt Cassandra C. , Spentzos Dimitrios , Choy Edwin , Hornicek Francis J. , Duan Zhenfeng
Published: April 2023

Characteristics of the chordoma patients
Supplementary Material and Methods from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Supplementary Material, Methods, and Figure Legend
Supplementary Video from First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas
Authors: Bonvalot Sylvie , Le Pechoux Cécile , De Baere Thierry , Kantor Guy , Buy Xavier , Stoeckle Eberhard , Terrier Philippe , Sargos Paul , Coindre Jean Michel , Lassau Nathalie , Ait Sarkouh Rafik , Dimitriu Mikaela , Borghi Elsa , Levy Laurent , Deutsch Eric , Soria Jean-Charles
Published: April 2023

NBTXR3 Injection _ DCE US. Dynamic contrast-enhanced ultrasonography (DCE-US) was performed to examine treatment-related changes to the tumor
Supplementary methods from PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
Authors: Lin Fan , de Gooijer Mark C. , Hanekamp Diana , Chandrasekaran Gayathri , Buil Levi C.M. , Thota Nishita , Sparidans Rolf W. , Beijnen Jos H. , Würdinger Tom , van Tellingen Olaf
Published: April 2023

File contains information on the methods used to establish murine glioma cell lines and how they have been used to assess the effects of the PI3K inhibitors
Supplementary Figure 1 from PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
Authors: Lin Fan , de Gooijer Mark C. , Hanekamp Diana , Chandrasekaran Gayathri , Buil Levi C.M. , Thota Nishita , Sparidans Rolf W. , Beijnen Jos H. , Würdinger Tom , van Tellingen Olaf
Published: April 2023

File contains data on the efficacy of the PI3K inhibitors against murine glioma derived cell lines
Supplementary Table 1 from First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas
Authors: Bonvalot Sylvie , Le Pechoux Cécile , De Baere Thierry , Kantor Guy , Buy Xavier , Stoeckle Eberhard , Terrier Philippe , Sargos Paul , Coindre Jean Michel , Lassau Nathalie , Ait Sarkouh Rafik , Dimitriu Mikaela , Borghi Elsa , Levy Laurent , Deutsch Eric , Soria Jean-Charles
Published: April 2023

Whole blood hafnium concentrations for each patient following NBTXR3 injection. Quantification of NBTXR3 in the blood was performed to evaluate passage into the systemic circulation. The hafnium component of NBTXR3 was quantified through inductively coupled plasma mass spectrometry (ICP-MS). Whole blood samples were collected on Day 1: before injection, immediately after the injection start, at the end of the injection, 5, 10, 15, 60, 120 and 240 minutes after completion of the injection; and on Day 2. Three additional blood samples were collected during radiotherapy, between the 11th and 20th radiotherapy sessions. One blood sample was also collected prior to surgery.
Table S1 from Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Authors: Ibrahimpasic Tihana , Xu Bin , Landa Iñigo , Dogan Snjezana , Middha Sumit , Seshan Venkatraman , Deraje Shyam , Carlson Diane L. , Migliacci Jocelyn , Knauf Jeffrey A. , Untch Brian , Berger Michael F. , Morris Luc , Tuttle R. Michael , Chan Timothy , Fagin James A. , Ghossein Ronald , Ganly Ian
Published: April 2023

List of 410 genes in IMPACT sequencing platform
Table S3 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

GAUSS response by genotype
Table S1 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

SPORE study population
Supplemental Figure 1 from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Authors: Benson Al B. , Kiss Igor , Bridgewater John , Eskens Ferry A.L.M. , Sasse Carolyn , Vossen Sandra , Chen Jihong , Van Sant Chip , Ball Howard A. , Keating Anne , Krivoshik Andrew
Published: April 2023

Patient Disposition
Supplemental Figure 2 from A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Authors: Zhang Yi , Schroeder Brock E. , Jerevall Piiha-Lotta , Ly Amy , Nolan Hannah , Schnabel Catherine A. , Sgroi Dennis C.
Published: April 2023

Supplemental Figure 2 shows a plot of the rate of overall 10-year (A,C) and late post-5-year distant recurrence (B,D) as a function of continuous BCIN+.
Figure S4 from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

RGD-specific mAbs inhibit activation of β1 integrin, cell adhesion, proliferation and invasion of melanoma and breast cancer cells
Supplemental Figure 1 from A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Authors: Zhang Yi , Schroeder Brock E. , Jerevall Piiha-Lotta , Ly Amy , Nolan Hannah , Schnabel Catherine A. , Sgroi Dennis C.
Published: April 2023

Supplemental Figure 1 shows the prognostic performance of BCIN+ for overall 15-year (A,C) and late post-5-year (B,D) any recurrence (local, regional or distant) in patients with 1-3 positive nodes.
Figure S2 from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

RGD-specific mAbs inhibit activation of β1 integrin, cell adhesion and proliferation only in CDH17-positive colon cancer cells.
Figure S1 from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

Functional characterization of CDH17 RGD-specific antibodies
Schematic diagram of Fc-fused IL-7 from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Figure 1. Schematic diagram of Fc-fused IL-7
supplementary Table S6 from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

Results of colorectal cell lines classification into BM1 and BM2.
supplementary Table S1 and S2 from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

Table S1: Definitions of mutation calls used in this study;Table S2: List of genes with non-zero coefficients obtained by the classifier used to categorize gene expression profiles into BM1 and BM2.
Supplementary Table S6 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

List of uniformly expressed genes in all 23 RNA-seq samples selected for qPCR validation in urine samples as reference markers.
Supplementary Table S2 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

Full list of differentially expressed genes identified in comparison of the 10 HG bladder cancer urine samples to 8 control urine samples based on urinary RNA-seq data in the urinary biomarker discovery.
Suppl Fig Table Legends from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Authors: Ozawa Hiroyuki , Ranaweera Ruchira S. , Izumchenko Evgeny , Makarev Eugene , Zhavoronkov Alex , Fertig Elana J. , Howard Jason D. , Markovic Ana , Bedi Atul , Ravi Rajani , Perez Jimena , Le Quynh-Thu , Kong Christina S. , Jordan Richard C. , Wang Hao , Kang Hyunseok , Quon Harry , Sidransky David , Chung Christine H.
Published: April 2023

Supplemental figure and table legends
Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Authors: Ibrahim Ahmed Atef , Schmithals Christian , Kowarz Erik , Köberle Verena , Kakoschky Bianca , Pleli Thomas , Kollmar Otto , Nitsch Scarlett , Waidmann Oliver , Finkelmeier Fabian , Zeuzem Stefan , Korf Horst-Werner , Schmid Tobias , Weigert Andreas , Kronenberger Bernd , Marschalek Rolf , Piiper Albrecht
Published: April 2023

Supplementary Fig. S2. Tumor hypoxia increases EMT markers in HepG2 xenografts. Nude mice bearing HepG2 xenografts were sacrificed and the tumors were removed from the animals. Frozen sections of the tumors were stained with anti-E-cadherin (red) and anti-CA9 (green) and Hoechst (blue) and were examined by CLSM. (Scale bar: 30 µm).
Supplemental Table S2: PK biologics oncology from Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies
Authors: Liston Dane R. , Davis Myrtle
Published: April 2023

An Excel file containing all biological drugs presented in Table 3 of the printed manuscript, including additional fields containing mechanism of action/target, MW, dose schedule, Clearance, Volume of distribution, year approved, full references to source data and drug product label, approved indications, additional notes.